A baicalein-chlorantraniliprole suspension and its preparation method

Abstract

This application relates to the field of pesticide technology, specifically disclosing an abamectin-chlorantraniliprole suspension and its preparation method. The abamectin-chlorantraniliprole suspension is mainly composed of the following raw materials in weight percentages: chlorantraniliprole 5-15%, abamectin 1-5%, glyceryl phosphorylcholine 1-2%, 1,3-dimethyl-2-imidazolinone 0.3-0.8%, polyether phosphate salt 2-4%, block polyether 1-3%, polycarboxylate 2-4%, xanthan gum 0.15-0.3%, magnesium aluminum silicate 0.5-2%, filler 0.5-2%, antifreeze 3-6%, antioxidant 0.5-2.5%, preservative 0.2-0.5%, organosilicon defoamer 0.1-0.5%, with the balance being water. This abamectin-chlorantraniliprole suspension features good storage stability, long shelf life, easy pouring and cleaning, strong wetting and penetrating properties, and high efficacy, meeting market demands.

Description

Technical Field

[0001] This application relates to the field of pesticide technology, and more specifically, to an abamectin-chlorantraniliprole suspension and its preparation method. Background Technology

[0002] In agriculture, pesticides play a crucial role in controlling crop diseases and pests, and ensuring crop yield and quality. Chlorantraniliprole, chemically known as 3-bromo-N-{4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl}-1-(3-chloro-2-pyridyl)-1H-pyrazole-5-amide, activates ryanodine receptors in pests, causing calcium ion channels to remain open. This results in the unrestricted release of intracellularly stored calcium ions into the sarcoplasm, leading to excessive muscle contraction, paralysis, and ultimately, death from energy depletion. Emamectin benzoate, on the other hand, enhances the activity of neurotransmitters, such as glutamate and γ-aminobutyric acid (GABA), allowing large amounts of chloride ions to enter nerve cells, causing cell dysfunction, disrupting nerve conduction, introducing irreversible paralysis, and ultimately leading to pest death. Insecticides such as chlorantraniliprole and abamectin have the advantages of being green, safe, and low in toxicity, and have been accepted and widely used in the market.

[0003] Currently, commercially available abamectin-chlorantraniliprole suspension concentrates typically contain chlorantraniliprole, abamectin, thickeners, antifreeze agents, antioxidants, preservatives, defoamers, and water. These raw materials are mixed and ground to obtain the abamectin-chlorantraniliprole suspension concentrate. The chlorantraniliprole and abamectin in this concentrate are mainly suspended in particulate form in the aqueous system, resulting in a less than ideal suspension rate. This leads to slightly poorer field control efficacy and affects the overall effectiveness of the pesticide. Summary of the Invention

[0004] To improve the suspension rate and field control effect of abamectin-chlorantraniliprole suspension, this application provides an abamectin-chlorantraniliprole suspension and its preparation method.

[0005] In a first aspect, this application provides an abamectin-chlorantraniliprole suspension, which adopts the following technical solution:

[0006] A chlorantraniliprole-emamectin suspension concentrate is mainly composed of the following raw materials in weight percentages: chlorantraniliprole 5-15%, emamectin 1-5%, glyceryl phosphorylcholine 1-2%, 1,3-dimethyl-2-imidazolinone 0.3-0.8%, polyether phosphate salt 2-4%, block polyether 1-3%, polycarboxylate 2-4%, xanthan gum 0.15-0.3%, magnesium aluminum silicate 0.5-2%, filler 0.5-2%, antifreeze 3-6%, antioxidant 0.5-2.5%, preservative 0.2-0.5%, organosilicon defoamer 0.1-0.5%, with the balance being water.

[0007] The abamectin-chlorantraniliprole suspension of this application, through the synergistic effect of the raw materials, has the characteristics of good storage stability, long shelf life, easy pouring, easy cleaning, strong wetting and penetration, and high efficacy, thus meeting market demand.

[0008] Chlorantraniliprole and abamectin are added to the raw materials. Both abamectin and chlorantraniliprole are insecticidal active ingredients, and both are mainly suspended in the aqueous system in particulate form. Utilizing their synergistic effect, they can effectively control pests. Furthermore, polyether phosphate salts, block polyethers, and polycarboxylate salts are added. These not only stabilize the active ingredients through electrostatic repulsion and steric hindrance, improving dispersibility, but also improve the compatibility between raw materials, reduce water separation, and improve wetting and penetration capabilities. Xanthan gum, magnesium aluminum silicate, and fillers are also added simultaneously, which can increase viscosity, improve flowability, stabilize the active ingredients, and reduce adhesion and sedimentation of the active ingredients. The resulting abamectin-chlorantraniliprole suspension concentrate has a chlorantraniliprole suspension rate >99%, an abamectin suspension rate >99%, a residue content after pouring <4%, and a residue content after washing <0.2%. It also contains glycerylphosphocholine and 1,3-dimethyl-2-imidazolinone, and utilizes the synergistic effect between the two to not only increase wetting and penetration capacity, but also to act directly on the cell surface, which can expand the intercellular space, fuse with cells and form delivery channels, accelerate the penetration of active ingredients, improve field control effect, and make the field control effect of abamectin-chlorantraniliprole suspension >91%.

[0009] Optionally, the polyether phosphate salt is selected from one or more of the following: fatty alcohol polyether phosphate potassium salt MOA-9PK, fatty alcohol polyether phosphate potassium salt MOA-3PK, fatty alcohol polyether phosphate potassium salt MAP-30K, phenolic ether phosphate potassium salt OP-10PK, phenolic ether phosphate potassium salt NP-10PK, and phenolic ether phosphate potassium salt TX-10PK.

[0010] Optionally, the block polyether is selected from one or more of Pluronic F-68, Pluronic F-127, Pluronic F-38, Pluronic P-123, Pluronic P-85, Pluronic P-84, Pluronic L-35, Pluronic L-44, and Pluronic L-64.

[0011] Optionally, the polycarboxylate is selected from one or more of sodium polycarboxylate HT-5040, sodium polycarboxylate SN-5040, polycarboxylate KLF-301, sodium polyacrylate Sokalan PA-30, and sodium polyacrylate PA-25.

[0012] By adopting the above technical solutions, the polyether phosphate salts, block polyethers, and polycarboxylates are optimized, facilitating their selection. Furthermore, the polyether phosphate salts, block polyethers, and polycarboxylates form an anionic, nonionic, and high-molecular-weight ternary dispersion system, enabling better dispersion and emulsification of chlorantraniliprole and abamectin, reducing aggregation and sedimentation. This allows chlorantraniliprole and abamectin to remain stably suspended in the aqueous system, increasing storage stability, facilitating pouring and cleaning, and improving wetting and penetration capabilities, thus promoting the full efficacy of the active ingredients.

[0013] Optionally, the filler is selected from one or more of silica, bentonite, kaolin, montmorillonite, diatomite, and attapulgite.

[0014] By adopting the above technical solutions, the packing material is optimized, facilitating its selection. Furthermore, the packing material effectively reduces the adhesion of active ingredients, improves dispersibility, reduces sedimentation, increases storage stability, and extends shelf life.

[0015] Optionally, the antifreeze agent is selected from one or more of ethylene glycol, propylene glycol, glycerol, sorbitol, and mannitol.

[0016] By adopting the above technical solution, the antifreeze is optimized, facilitating its selection. Furthermore, the antifreeze exhibits good low-temperature fluidity, reducing the likelihood of freezing of the abamectin-chlorantraniliprole suspension at low temperatures, ensuring it remains liquid within a certain low-temperature range, thus facilitating its storage and use.

[0017] Optionally, the antioxidant is selected from one or more of 2,6-di-tert-butyl-p-cresol, butylated hydroxyanisole, tert-butylhydroquinone, tocopherol, tea polyphenols, and ascorbic acid.

[0018] Optionally, the preservative is selected from one or more of methylisothiazolinone, 1,2-benzisothiazolin-3-one, sodium benzoate, potassium sorbate, methylisothiazolinone, and chloromethylisothiazolinone.

[0019] By adopting the above technical solutions, antioxidants and preservatives are optimized, facilitating their selection. Furthermore, antioxidants possess excellent antioxidant properties, delaying the oxidation of active ingredients, while preservatives have bactericidal properties, inhibiting the growth and reproduction of microorganisms, thus ensuring the quality and storage stability of the abamectin-chlorantraniliprole suspension.

[0020] Optionally, the silicone defoamer is selected from one or more of silicone defoamers BYK-022, BYK-024, BYK-025, BYK-028, BYK-141, BYK-1724, and BYK-1730.

[0021] By adopting the above technical solution, the silicone defoamer is optimized, facilitating its selection. Furthermore, the silicone defoamer enables rapid foam dissipation and inhibits foam regeneration for an extended period, ensuring the stability and uniformity of the abamectin-chlorantraniliprole suspension.

[0022] Secondly, this application provides a method for preparing the aforementioned abamectin-chlorantraniliprole suspension, employing the following technical solution:

[0023] A method for preparing the emamectin benzoate-chlorantraniliprole suspension includes the following steps:

[0024] Chlorantraniliprole, abamectin, glycerylphosphocholine, 1,3-dimethyl-2-imidazolinone, polyether phosphate salt, block polyether, polycarboxylate, xanthan gum, magnesium aluminum silicate, filler, antifreeze, antioxidant, preservative, silicone defoamer, and water are mixed and ground to obtain abamectin-chlorantraniliprole suspension.

[0025] By adopting the above technical solution, the raw materials are mixed and ground, which facilitates the preparation of abamectin-chlorantraniliprole suspension.

[0026] Optionally, in the preparation method of abamectin-chlorantraniliprole suspension, the particles are ground to a particle size D90 < 5 μm.

[0027] In summary, this application has at least the following beneficial effects:

[0028] 1. The abamectin-chlorantraniliprole suspension concentrate of this application, through the synergistic effect between the raw materials, achieves a chlorantraniliprole suspension rate >99%, an abamectin suspension rate >99%, a residue content after dumping <4%, a residue content after washing <0.2%, and a field control efficacy >91%. It features good storage stability, long shelf life, easy dumping and cleaning, strong wetting and penetrating properties, and high efficacy, thus meeting market demands.

[0029] 2. The abamectin-chlorantraniliprole suspension concentrate of this application simultaneously adds polyether phosphate salt, block polyether, and polycarboxylate to the raw materials, forming a ternary dispersion system of anionic, nonionic, and high molecular weight, effectively improving dispersibility, compatibility, and reducing water separation. It also simultaneously adds glycerol phosphorylcholine and 1,3-dimethyl-2-imidazolinone, utilizing the synergistic effect between the two to increase wetting and penetration capabilities. Furthermore, it can expand intercellular spaces, fuse with cells, and form delivery channels, accelerating the penetration of active ingredients and allowing chlorantraniliprole and abamectin to fully exert their efficacy, thus improving field control effects. Detailed Implementation

[0030] To make this application easier to understand, the following detailed description will be provided with reference to embodiments. These embodiments are for illustrative purposes only and are not intended to limit the scope of application of this application. Unless otherwise specified, the raw materials or components used in this application can be obtained commercially or by conventional methods. Example

[0031] Table 1. Amounts of each raw material used in abamectin-chlorantraniliprole suspension concentrate (unit: ×10g)

[0032]

[0033] Example 1

[0034] A baicalein-chlorantraniliprole suspension concentrate, the raw materials and their proportions are shown in Table 1.

[0035] Among them, the polyether phosphate salt is selected from the potassium salt of fatty alcohol polyether phosphate MOA-9PK; the block polyether is selected from Pluronic F-68; the polycarboxylate is selected from the sodium salt of polycarboxylate HT-5040; the xanthan gum is fast-dissolving xanthan gum and is selected from Jiangsu Aofu Biotechnology Co., Ltd.; the filler is selected from silica; the antifreeze agent is selected from ethylene glycol; the antioxidant is selected from 2,6-di-tert-butyl-p-cresol; the preservative is selected from methylisothiazolinone; and the silicone defoamer is selected from silicone defoamer BYK-024.

[0036] A method for preparing an abamectin-chlorantraniliprole suspension includes the following steps:

[0037] Add chlorantraniliprole, abamectin, glycerylphosphatidylcholine, 1,3-dimethyl-2-imidazolinone, polyether phosphate salt, block polyether, polycarboxylate, xanthan gum, magnesium aluminum silicate, filler, antifreeze, antioxidant, preservative, and silicone defoamer to water, and stir for 40 min. Then grind at 2000 r / min and 10℃ until the particle size D90 < 5 μm to obtain abamectin-chlorantraniliprole suspension.

[0038] Example 2

[0039] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0040] Example 3

[0041] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0042] Example 4

[0043] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0044] Example 5

[0045] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0046] Example 6

[0047] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0048] Example 7

[0049] A type of abamectin-chlorantraniliprole suspension differs from Example 1 in that the raw material ratio of the abamectin-chlorantraniliprole suspension is different, and the raw material ratio of the abamectin-chlorantraniliprole suspension is shown in Table 1.

[0050] Comparative Example

[0051] Comparative Example 1

[0052] An abamectin-chlorantraniliprole suspension concentrate, which uses 11.6% abamectin-chlorantraniliprole suspension concentrate and is selected from Shandong Zhongxin Kenong.

[0053] Comparative Example 2

[0054] An abamectin-chlorantraniliprole suspension differs from Example 1 in that an equal amount of water replaces glycerol phosphorylcholine and 1,3-dimethyl-2-imidazolinone in the raw materials of the abamectin-chlorantraniliprole suspension.

[0055] Comparative Example 3

[0056] An abamectin-chlorantraniliprole suspension differs from Example 1 in that an equal amount of glycerol phosphorylcholine is used to replace 1,3-dimethyl-2-imidazolinone in the raw materials of the abamectin-chlorantraniliprole suspension.

[0057] Comparative Example 4

[0058] An abamectin-chlorantraniliprole suspension differs from Example 1 in that an equal amount of 1,3-dimethyl-2-imidazolinone replaces glycerol phosphorylcholine in the raw materials of the abamectin-chlorantraniliprole suspension.

[0059] Comparative Example 5

[0060] An abamectin-chlorantraniliprole suspension concentrate differs from Example 1 in that an equal amount of N-methylpyrrolidone is used instead of 1,3-dimethyl-2-imidazolinone in the raw materials of the abamectin-chlorantraniliprole suspension concentrate.

[0061] Comparative Example 6

[0062] An abamectin-chlorantraniliprole suspension concentrate differs from Example 1 in that an equal amount of laurocapram is used to replace 1,3-dimethyl-2-imidazolinone in the raw materials of the abamectin-chlorantraniliprole suspension concentrate.

[0063] Comparative Example 7

[0064] An abamectin-chlorantraniliprole suspension differs from Example 1 in that an equal amount of phosphatidylcholine is used instead of glycerol phosphorylcholine in the raw materials of the abamectin-chlorantraniliprole suspension.

[0065] Performance testing

[0066] (1) The abamectin-chlorantraniliprole suspensions obtained in Examples 1-7 and Comparative Examples 1-7 were taken as samples, and the following performance tests were performed on the abamectin-chlorantraniliprole suspensions. The test results are shown in Tables 2 and 3.

[0067] In accordance with GB / T14825-2006, the suspension rates of chlorantraniliprole and emamectin benzoate in the abamectin-chlorantraniliprole suspension were tested.

[0068] The thermal storage stability was determined by the following method: the abamectin-chlorantraniliprole suspension was left to stand at 54℃ for 14 days, the water separation was observed, and the thermal storage water separation rate was calculated. A water separation rate of 0 indicated that there was no water separation.

[0069] Low-temperature stability was assessed using the following method: the abamectin-chlorantraniliprole suspension was left to stand at 2°C for 14 days, and the water separation was observed. The low-temperature water separation rate was calculated, and a water separation rate of 0 indicated no water separation.

[0070] Freeze-thaw stability was determined using the following method: the abamectin-chlorantraniliprole suspension was frozen by standing at -18℃ for 4 hours, and then thawed by standing at 25℃ for 24 hours. The water separation was observed and the freeze-thaw water separation rate was calculated. A water separation rate of 0 indicates no water separation.

[0071] The particle size D90 of abamectin-chlorantraniliprole suspension was determined using a laser particle size analyzer.

[0072] According to GB / T28137-2011, the sustained foam volume of abamectin-chlorantraniliprole suspension was tested. A smaller sustained foam volume indicates that the foam on the surface of the abamectin-chlorantraniliprole suspension dissipates more easily.

[0073] According to GB / T31737-2015, the residue content after pouring and after washing of abamectin-chlorantraniliprole suspension were tested. The lower the residue content after pouring and after washing, the easier the abamectin-chlorantraniliprole suspension is to pour.

[0074] The wetting time of the canvas sheet was determined by immersing the canvas sheet in an abamectin-chlorantraniliprole suspension and calculating the wetting time.

[0075] The penetration depth of the popsicle sticks was determined by the following method: the popsicle sticks were immersed in a baicalein-chlorantraniliprole suspension, left to stand for 1 day, and then removed to test the penetration depth.

[0076] The field control effect was assessed using the following method: Cabbage was pre-planted in the experimental field; the main pest of cabbage is the diamondback moth. Abamectin-chlorantraniliprole suspension was diluted 1000 times to obtain a spray solution. This spray solution was applied to the cabbage to control the diamondback moth. The application rate was 50 L / acre. Seven days after spraying, samples were taken at designated locations, and the field control effect was calculated. Simultaneously, a blank control group was established, in which water was used instead of the abamectin-chlorantraniliprole suspension.

[0077] Pest population reduction rate (%) = (Number of pests before application - Number of pests after application) / Number of pests before application × 100%.

[0078] Field control effect (%) = (Pest population reduction rate in the pesticide application area - Pest population reduction rate in the blank control area) / (100 - Pest population reduction rate in the blank control area) × 100%.

[0079] Table 2 Test Results

[0080]

[0081] Table 3 Test Results

[0082]

[0083] As can be seen from Tables 2 and 3, the abamectin-chlorantraniliprole suspension concentrate of this application has the following characteristics: chlorantraniliprole suspension rate >99%, abamectin suspension rate >99%, hot storage water separation rate <6%, low temperature water separation rate 0%, freeze-thaw water separation rate <8%, particle size D90 <5μm, hot storage particle size D90 <5μm, sustained foaming volume <25mL, residue content after pouring <4%, residue content after washing <0.2%, canvas wetting time <210s, popsicle stick penetration depth >4cm, and field control effect >91%. These characteristics make the abamectin-chlorantraniliprole suspension concentrate have good storage stability, long shelf life, easy pouring, easy cleaning, strong wetting, strong penetration, and high efficacy, meeting market demands.

[0084] Example 1 and Comparative Examples 2-3 were compared. In Comparative Example 3, glycerol phosphorylcholine was added to the raw materials of the abamectin-chlorantraniliprole suspension compared to Comparative Example 2; in Comparative Example 4, 1,3-dimethyl-2-imidazolinone was added to the raw materials of the abamectin-chlorantraniliprole suspension compared to Comparative Example 2; and in Example 1, both glycerol phosphorylcholine and 1,3-dimethyl-2-imidazolinone were added to the raw materials of the abamectin-chlorantraniliprole suspension compared to Comparative Example 2. This demonstrates that the simultaneous addition of glycerol phosphorylcholine and 1,3-dimethyl-2-imidazolinone to the raw materials, and their synergistic effect, significantly increases the wetting time of the canvas sheet, the penetration depth of the popsicle stick, and improves the field control efficacy.

[0085] Example 1 and Comparative Examples 5-6 were compared. In Comparative Example 5, N-methylpyrrolidone was added to the raw material of the abamectin-chlorantraniliprole suspension; in Comparative Example 6, laurocapram was added; and in Example 1, 1,3-dimethyl-2-imidazolinone was added. This shows that, compared to adding N-methylpyrrolidone or laurocapram to the raw material, adding 1,3-dimethyl-2-imidazolinone further improves wetting and penetration, as well as field efficacy. Similarly, in conjunction with Comparative Example 7, compared to adding phosphatidylcholine to the raw material, adding glycerophosphatidylcholine also further improves wetting and penetration, and enhances efficacy, resulting in the abamectin-chlorantraniliprole suspension exhibiting superior overall performance.

[0086] It should be noted that the embodiments described above are only for explaining this application and do not constitute any limitation on this application. This application has been described with reference to typical embodiments, but it should be understood that the terms used therein are descriptive and explanatory terms, not limiting terms. Modifications can be made to this application within the scope of the claims, and amendments can be made without departing from the scope and spirit of this application. Although the application described herein relates to specific methods, materials, and embodiments, it does not mean that this application is limited to the specific examples disclosed herein; on the contrary, this application can be extended to all other methods and applications with the same function.

Claims

1. An emamectin benzoate-chlorantraniliprole suspension concentrate characterized by: It is made of the following raw materials by weight percentage: chlorantraniliprole 5-15%, emamectin benzoate 1-5%, glycerophosphoryl choline 1-2%, 1,3-dimethyl-2-imidazolidinone 0.3-0.8%, polyether phosphate salt 2-4%, block polyether 1-3%, polycarboxylate 2-4%, xanthan gum 0.15-0.3%, magnesium aluminum silicate 0.5-2%, filler 0.5-2%, antifreeze 3-6%, antioxidant 0.5-2.5%, preservative 0.2-0.5%, silicone defoamer 0.1-0.5%, and the balance is water; The polyether phosphate salt is selected from one or more of fatty alcohol polyether phosphate potassium salt MOA-9PK, fatty alcohol polyether phosphate potassium salt MOA-3PK, fatty alcohol polyether phosphate potassium salt MAP-30K, phenolic ether phosphate potassium salt OP-10PK, phenolic ether phosphate potassium salt NP-10PK, and phenolic ether phosphate potassium salt TX-10PK; the block polyether is selected from one or more of Pluronic F-68, Pluronic F-127, Pluronic F-38, Pluronic P-123, Pluronic P-85, Pluronic P-84, Pluronic L-35, Pluronic L-44, and Pluronic L-64; and the polycarboxylate is selected from one or more of polycarboxylic acid sodium salt HT-5040, polycarboxylic acid sodium salt SN-5040, polycarboxylic acid salt KLF-301, polyacrylic acid sodium salt Sokalan PA-30, and polyacrylic acid sodium salt PA-25.

2. The emamectin benzoate-chlorantraniliprole suspension agent according to claim 1, characterized by: The filler is selected from one or more of white carbon black, bentonite, kaolin, montmorillonite, diatomite, and attapulgite.

3. The emamectin benzoate-chlorantraniliprole suspension agent according to claim 1, characterized by: The antifreeze is selected from one or more of ethylene glycol, propylene glycol, glycerol, and sorbitol.

4. The emamectin benzoate-chlorantraniliprole suspension agent according to claim 1, characterized by: The antioxidant is selected from one or more of 2,6-di-tert-butyl-p-cresol, butylated hydroxyanisole, tert-butyl hydroquinone, tocopherol, tea polyphenol, and ascorbic acid.

5. The emamectin benzoate-chlorantraniliprole suspension agent according to claim 1, characterized by: The preservative is selected from one or more of methylisothiazolinone, 1,2-benzisothiazolin-3-one, sodium benzoate, potassium sorbate, methylisothiazolinone, and chloromethylisothiazolinone.

6. The emamectin benzoate-chlorantraniliprole suspension agent according to claim 1, characterized by: The silicone defoamer is selected from one or more of silicone defoamer BYK-022, silicone defoamer BYK-024, silicone defoamer BYK-025, silicone defoamer BYK-028, silicone defoamer BYK-141, silicone defoamer BYK-1724, and silicone defoamer BYK-1730.

7. A method of preparing the emamectin benzoate-chlorantraniliprole suspension concentrate according to any one of claims 1 to 6, characterized by: The method comprises the following steps: Mixing chlorantraniliprole, emamectin benzoate, glycerophosphoryl choline, 1,3-dimethyl-2-imidazolidinone, polyether phosphate salt, block polyether, polycarboxylate, xanthan gum, magnesium aluminum silicate, filler, antifreeze, antioxidant, preservative, silicone defoamer, and water, and grinding to obtain the emamectin benzoate-chlorantraniliprole suspension.

Images